Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air(®).

Autores da FMUP
Participantes de fora da FMUP
- Bousquet J
- Anto JM
- Bedbrook A
- Czarlewski W
- Ansotegui IJ
- Bergmann KC
- Braido F
- Brussino L
- Cecchi L
- Loureiro CC
- Cruz AA
- Devillier P
- Fiocchi A
- Gemicioglu B
- Haahtela T
- Ivancevich JC
- Klimek L
- Kulus M
- Kuna P
- Kupczyk M
- Kvedariene V
- Larenas-Linnemann DE
- Louis G
- Louis R
- Makris M
- Morais-Almeida M
- Niedoszytko M
- Ohta K
- Ollert M
- Papadopoulos N
- Patella V
- Pétré B
- Pfaar O
- Puggioni F
- Quirce S
- Regateiro FS
- Roche N
- Rouadi PW
- Samolinski B
- Sastre J
- Schleich F
- Scichilone N
- Taborda-Barata L
- Toppila-Salmi S
- Valiulis A
- Vardaloglu Koyuncu I
- Ventura MT
- Yorgancioglu A
- Zuberbier T
Unidades de investigação
Abstract
Patient-reported outcome measures (PROMs) are used to assess a patient's health status at a particular point in time. They are essential in the development of person-centred care. This paper reviews studies performed on PROMs for assessing AR and asthma control, in particular VAS scales that are included in the app MASK-air(®) (Mobile Airways Sentinel networK) for asthma and rhinitis. VASs were initially developed on paper and pencil and tested for their criterion validity, cut-offs and responsiveness. Then, a multicentric, multinational, double-blind, placebo-controlled, randomised control trial (DB-PC-RCT) using an electronic VAS form was carried out. Finally, with the development of MASK-air(®) in 2015, previously validated VAS questions were adapted to the digital format and further methodologic evaluations were performed. VAS for asthma, rhinitis, conjunctivitis, work and EQ-5D are included in the app. Additionally, two control-medication scores for allergic symptoms of asthma (e-DASTHMA) were validated for their criterion validity, cut-offs and responsiveness.
© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Dados da publicação
- ISSN/ISSNe:
- 2045-7022, 2045-7022
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.1002/clt2.12390
- Link para outro recurso:
- www.scopus.com
Clinical and Translational Allergy John Wiley & Sons Inc.
Documentos
- Não há documentos
Filiações
Keywords
- EQ-5D; asthma; digital health; rhinitis; visual analogue scale
Campos de estudo
Proyectos asociados
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021
Effect of a Mobile App on Improving Asthma Control in Adolescents and Adults With Persistent Asthma: A Pilot Randomized Multicentre, Superiority Clinical Trial (mINSPIRERS) - NCT05129527
Investigador Principal: João de Almeida Lopes da Fonseca
Ensaio Clínico Académico (mINSPIRERS) . 2021
Utilização em estudos observacionais do Registo de Asma Grave Portugal.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Observacional Académico (RAG) . 2020
Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (CRC SHARP).
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (SHARP) . European Respiratory Society . 2021
Multidimensional phenotyping of severe asthma patients and its impact on disease control and therapeutic response - analysis from the Portuguese Severe Asthma Registry.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-SPP-GSK) . SPPneumologia . 2022
BREATHE - An oBservational, pRimary data study to characterize severe AsThma pHenotypes and assEss disease burden across the EUCAN region.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-AZ-BREATHE) . AstraZeneca . 2022
Seroprevalence of SARS-CoV-2 and assessment of epidemiologic determinants in Portuguese municipal workers
Investigador Principal: Bernardo Manuel De Sousa Pinto
Estudo Clínico Académico (SARS-CoV-2) . 2021
Efficiency in Spine Care ? Assessing outcomes and costs to inform healthcare improvement
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2022
Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Citar a publicação
Bousquet J,Sousa B,Anto JM,Bedbrook A,Czarlewski W,Ansotegui IJ,Bergmann KC,Braido F,Brussino L,Cecchi L,Loureiro CC,Cruz AA,Devillier P,Fiocchi A,Gemicioglu B,Haahtela T,Ivancevich JC,Klimek L,Kulus M,Kuna P,Kupczyk M,Kvedariene V,Larenas DE,Louis G,Louis R,Makris M,Morais M,Niedoszytko M,Ohta K,Ollert M,Papadopoulos N,Patella V,Pétré B,Pfaar O,Puggioni F,Quirce S,Regateiro FS,Roche N,Rouadi PW,Samolinski B,Sastre J,Schleich F,Scichilone N,Taborda L,Toppila S,Valiulis A,Vardaloglu I,Ventura MT,Yorgancioglu A,Fonseca JA,Zuberbier T. Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air(®). Clin. Transl. Allergy. 2024. 14. (9):e12390. IF:4,400. (2).